Evommune EVMN
NYSE EVMN
$6.88 -0.31 (-4.31%)
At close: Oct 2, 2026 · 4:00 PM EDT

Evommune (EVMN) Cash from Investing Activities (2024 - 2026)

Updated

Evommune (EVMN) reported Cash from Investing Activities of $31.29 million for Q2 2026, up 73.9% from $18 million a year earlier.

Analysis

Evommune (EVMN) Cash from Investing Activities (2024 - 2026) Analysis & Trends

Over the twelve months ended Jun 30, 2026, Evommune's Cash from Investing Activities came in at -$200.87 million; for FY2025, it came in at -$115.31 million.

  • By year, Cash from Investing Activities came in at -$3.99 million in FY2024.
  • Per Business Quant data, the three quarters before Q2 2026 came in at -$85.36 million (Q1 2026), -$122.9 million (Q4 2025) and -$23.91 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn -15.40 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn -1.11 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn -1.20 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn -5.60 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn -3.11 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn -2.91 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn -569.00 Mn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -10.35 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 2.11 Bn
10 Evommune 249.62 Mn -387.90 Mn - 31.29 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 31.29 Mn
Mar 31, 2026 -85.36 Mn
Dec 31, 2025 -122.90 Mn
Sep 30, 2025 -23.91 Mn
Jun 30, 2025 18.00 Mn
Mar 31, 2025 13.50 Mn
Dec 31, 2024 -33.08 Mn
API Access

Evommune Cash from Investing Activities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-investing-activities&ticker=EVMN&period=max&api_key=YOUR_API_KEY